Risks of Lynch Syndrome Cancers for MSH6 Mutation Carriers

Background: Germline mutations in MSH6 account for 10%-20% of Lynch syndrome colorectal cancers caused by hereditary DNA mismatch repair gene mutations. Because there have been only a few studies of mutation carriers, their cancer risks are uncertain.

Methods: We identified 113 families of MSH6 mutation carriers from five countries that we ascertained through family cancer clinics and population-based cancer registries. Mutation status, sex, age, and histories of cancer, polypectomy, and hysterectomy were sought from 3104 of their relatives. Age-specific cumulative risks for carriers and hazard ratios (HRs) for cancer risks of carriers, compared with those of the general population of the same country, were estimated by use of a modified segregation analysis with appropriate conditioning depending on ascertainment.

Results: For MSH6 mutation carriers, the estimated cumulative risks to ages 70 and 80 years, respectively, were as follows: for colorectal cancer, 22% (95% confidence interval [CI] = 14% to 32%) and 44% (95% CI = 28% to 62%) for men and 10% (95% CI = 5% to 17%) and 20% (95% CI = 11% to 35%) for women; for endometrial cancer, 26% (95% CI = 18% to 36%) and 44% (95% CI = 30% to 58%); and for any cancer associated with Lynch syndrome, 24% (95% CI = 16% to 37%) and 47% (95% CI = 32% to 66%) for men and 40% (95% CI = 32% to 52%) and 65% (95% CI = 53% to 78%) for women. Compared with incidence for the general population, MSH6 mutation carriers had an eightfold increased incidence of colorectal cancer (HR = 7.6, 95% CI = 5.4 to 10.8), which was independent of sex and age. Women who were MSH6 mutation carriers had a 26-fold increased incidence of endometrial cancer (HR = 25.5, 95% CI = 16.8 to 38.7) and a sixfold increased incidence of other cancers associated with Lynch syndrome (HR = 6.0, 95% CI = 3.4 to 10.7).

Conclusion: We have obtained precise and accurate estimates of both absolute and relative cancer risks for MSH6 mutation carriers.

Citing Articles

Involvement of platelet signaling pathways in colorectal cancer and new therapeutic targets.

Bonfitto P, Rodrigues B, Siqueira N, Genaro L, Rodrigues B, Oliveira P Am J Cancer Res. 2024; 14(11):5133-5153.

PMID: 39659922 PMC: 11626285. DOI: 10.62347/PJNU8987.

Diagnostic Performance of Faecal Immunochemical Testing (FIT) in Patients with Lynch Syndrome Scheduled for Colonoscopic Surveillance.

Gerrard A, Maeda Y, Strachan J, Speake D, Dunlop M, Din F Diagnostics (Basel). 2024; 14(21).

PMID: 39518398 PMC: 11545718. DOI: 10.3390/diagnostics14212431.

Characteristics of Cancer in Subjects Carrying Lynch Syndrome-Associated Gene Variants in Taiwanese Population: A Hospital-Based Study in Taiwan.

Chen Y, Hsiao T, Lin W, Liao Y, Liao S, Tsai H Cancers (Basel). 2024; 16(21).

PMID: 39518119 PMC: 11544957. DOI: 10.3390/cancers16213682.

Influence of Genetic Polymorphisms on the Age at Cancer Diagnosis in a Homogenous Lynch Syndrome Cohort of Individuals Carrying the :c.1528C>T South African Founder Variant.

Ndou L, Chambuso R, Algar U, Goldberg P, Boutall A, Ramesar R Biomedicines. 2024; 12(10).

PMID: 39457514 PMC: 11505229. DOI: 10.3390/biomedicines12102201.

Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.

Trembath H, Yeh J, Lopez N Cancer Treat Res. 2024; 192:305-418.

PMID: 39212927 DOI: 10.1007/978-3-031-61238-1_15.

References

Southey M, Jenkins M, Mead L, Whitty J, Trivett M, Tesoriero A . Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol. 2005; 23(27):6524-32. DOI: 10.1200/JCO.2005.04.671. View

Lu K, Schorge J, Rodabaugh K, Daniels M, Sun C, Soliman P . Prospective determination of prevalence of lynch syndrome in young women with endometrial cancer. J Clin Oncol. 2007; 25(33):5158-64. DOI: 10.1200/JCO.2007.10.8597. View

Devlin L, Graham C, Price J, Morrison P . Germline MSH6 mutations are more prevalent in endometrial cancer patient cohorts than hereditary non polyposis colorectal cancer cohorts. Ulster Med J. 2008; 77(1):25-30. PMC: 2397009. View

Myrhoj T, Andersen M, Bernstein I . Screening for urinary tract cancer with urine cytology in Lynch syndrome and familial colorectal cancer. Fam Cancer. 2008; 7(4):303-7. DOI: 10.1007/s10689-008-9193-9. View

Jass J . Hereditary Non-Polyposis Colorectal Cancer: the rise and fall of a confusing term. World J Gastroenterol. 2006; 12(31):4943-50. PMC: 4087395. DOI: 10.3748/wjg.v12.i31.4943. View

Carayol J, Khlat M, Maccario J, Bonaiti-Pellie C . Hereditary non-polyposis colorectal cancer: current risks of colorectal cancer largely overestimated. J Med Genet. 2002; 39(5):335-9. PMC: 1735123. DOI: 10.1136/jmg.39.5.335. View

Dunlop M, Farrington S, Carothers A, Wyllie A, Sharp L, Burn J . Cancer risk associated with germline DNA mismatch repair gene mutations. Hum Mol Genet. 1997; 6(1):105-10. DOI: 10.1093/hmg/6.1.105. View

Hampel H, Frankel W, Panescu J, Lockman J, Sotamaa K, Fix D . Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006; 66(15):7810-7. DOI: 10.1158/0008-5472.CAN-06-1114. View

Hampel H, Frankel W, Martin E, Arnold M, Khanduja K, Kuebler P . Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352(18):1851-60. DOI: 10.1056/NEJMoa043146. View

10.

Lindor N, Burgart L, Leontovich O, Goldberg R, Cunningham J, Sargent D . Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002; 20(4):1043-8. DOI: 10.1200/JCO.2002.20.4.1043. View

11.

Berends M, Wu Y, Sijmons R, van der Sluis T, Ek W, Ligtenberg M . Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis. J Clin Oncol. 2003; 21(23):4364-70. DOI: 10.1200/JCO.2003.04.094. View

12.

Ewens W, Shute N . Remarks on ascertainment. Genet Epidemiol. 1989; 6(1):89-93. DOI: 10.1002/gepi.1370060117. View

13.

Schaid D, McDonnell S, Blute M, Thibodeau S . Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet. 1998; 62(6):1425-38. PMC: 1377141. DOI: 10.1086/301862. View

14.

Quehenberger F, Vasen H, van Houwelingen H . Risk of colorectal and endometrial cancer for carriers of mutations of the hMLH1 and hMSH2 gene: correction for ascertainment. J Med Genet. 2005; 42(6):491-6. PMC: 1736072. DOI: 10.1136/jmg.2004.024299. View

15.

Newcomb P, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R . Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(11):2331-43. DOI: 10.1158/1055-9965.EPI-07-0648. View

16.

Hampel H, Panescu J, Lockman J, Sotamaa K, Fix D, Comeras I . Comment on: Screening for Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) among Endometrial Cancer Patients. Cancer Res. 2007; 67(19):9603. DOI: 10.1158/0008-5472.CAN-07-2308. View

17.

Buttin B, Powell M, Mutch D, Babb S, Huettner P, Bocker Edmonston T . Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet. 2004; 74(6):1262-9. PMC: 1182090. DOI: 10.1086/421332. View

18.

Hendriks Y, de Jong A, Morreau H, Tops C, Vasen H, Wijnen J . Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): a guide for clinicians. CA Cancer J Clin. 2006; 56(4):213-25. DOI: 10.3322/canjclin.56.4.213. View

19.

Vasen H, Moslein G, Alonso A, Bernstein I, Bertario L, Blanco I . Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet. 2007; 44(6):353-62. PMC: 2740877. DOI: 10.1136/jmg.2007.048991. View

20.

Lindor N, Petersen G, Hadley D, Kinney A, Miesfeldt S, Lu K . Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA. 2006; 296(12):1507-17. DOI: 10.1001/jama.296.12.1507. View